Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

First US forum gathers doctors and children who no longer need insulin

Twenty-five families who have overcome diabetes caused by a defect in a single gene will gather at "Celebrating the Miracles," a University of Chicago symposium for patients, parents and physicians. The first Monogenic Diabetes Forum is designed to review scientific studies, celebrate treatment successes, stress the importance of a genetic diagnosis for children diagnosed before age one, and exchange tips on how to make the most of a new concept--life without insulin injections.

3 Jul 2010

MabCent finds extraordinary life forms in the Arctic

During its short existence the Centre on Marine Bioactives and Drug Discovery (MabCent) in Tromsø has analysed some 70,000 fractions of Arctic marine organisms. Patents on two molecules have been applied for and applications for another 20 will soon follow.

3 Jul 2010

FDA issues consumer update on safety alerts

The Food and Drug Administration (FDA) has issued safety alerts about a number of products.

3 Jul 2010

Children's Hospital Boston researchers reprogram adult blood cells into iPS cells

In findings likely to make it easier and faster for stem cell biologists to generate patient-specific embryonic-like stem cells, researchers at Children's Hospital Boston have reprogrammed adult blood cells into induced pluripotent stem (iPS) cells.

2 Jul 2010

Pay-for-performance program may cause inequalities among healthcare providers

Pay-for-performance is an increasingly popular approach to improving health care quality. But the planned nationwide implementation of institutional bonuses mandated under federal health care reform threatens to act as a "reverse Robin Hood," potentially causing hospitals in less-advantaged regions to lose funds to health care facilities in more affluent areas of the country, according to a study published in the academic journal PLoS Medicine.

2 Jul 2010

Two laboratory methods for Drosophila Neurobiology featured in Cold Spring Harbor Protocols journal

Cold Spring Harbor Laboratory's Neurobiology of Drosophila course (http://meetings.cshl.edu/courses/c-dros10.shtml) has served as the training ground for a generation of scientists tackling these complex problems. A new laboratory manual based on the protocols and background information taught in the course promises to spread these techniques to a wider audience. Two of the methods from the manual are featured in the July issue of the journal Cold Spring Harbor Protocols.

2 Jul 2010

Book on governance, social justice and epidemic diseases

Recent disease events such as SARS, H1N1 and avian influenza, and haemorrhagic fevers have focussed policy and public concern as never before on epidemics and so-called 'emerging infectious diseases'. Understanding and responding to these often unpredictable events have become major challenges for local, national and international bodies.

2 Jul 2010

Scientists explain mechanism behind acute myeloid leukemia

New research by scientists at Cold Spring Harbor Laboratory (CSHL) has illuminated in fine detail one of the genetic paths that leads to a particularly aggressive form of leukemia.

2 Jul 2010

Diagnostic Hybrids receives Chinese SFDA approval for D3 Ultra DFA Respiratory Virus Screening and ID Kit

Diagnostic Hybrids, a Quidel Company, received approval from the People's Republic of China's State Food and Drug Administration (SFDA) for its D3 Ultra DFA Respiratory Virus Screening and ID Kit. The D3 Ultra DFA Respiratory Virus Screening and ID Kit is a direct fluorescence assay (DFA) that provides rapid, sensitive and specific screening and identification of Influenza A, Influenza B, Parainfluenza 1, 2, & 3, Respiratory Syncytial Virus and Adenovirus.

1 Jul 2010

Advanced Life Sciences prices securities offering

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has established the pricing terms of its proposed offering of units.

1 Jul 2010

AstraZeneca announces new support program for patients on ARIMIDEX

AstraZeneca today announced a new patient support program for postmenopausal women with hormone receptor-positive early breast cancer who are prescribed ARIMIDEX. The program is designed to provide eligible patients with instant discounts, potentially saving the patient up to $300.

1 Jul 2010

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.

1 Jul 2010

Ecolab launches Virasept to treat Clostridium difficile spores

Ecolab Inc. today announced the launch of Virasept, Ecolab's first ready-to-use (no mixing required) hard surface disinfectant approved by the U.S. Environmental Protection Agency to be effective against Clostridium difficile spores.

1 Jul 2010

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai Inc. announced today preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults.

1 Jul 2010

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment of the first patient in a Phase 2 study with CXA-201. This multicenter, double-blind, randomized, study will compare the safety and efficacy of intravenous CXA-201 with an active comparator in patients with complicated intra-abdominal Infections (cIAI). This international study is expected to enroll 120 patients.

1 Jul 2010

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.

30 Jun 2010

Investment report on BioCryst Pharmaceuticals

MicroStockProfit.com announces an investment report featuring BioCryst Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

30 Jun 2010

Medivir's rights issue changes number of shares and votes

The number of shares and the number of votes in Medivir have changed as a result of the rights issue carried out by the company as well as the exercise of employee stock options.

30 Jun 2010

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.

30 Jun 2010

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.

30 Jun 2010

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

First US forum gathers doctors and children who no longer need insulin

MabCent finds extraordinary life forms in the Arctic

FDA issues consumer update on safety alerts

Children's Hospital Boston researchers reprogram adult blood cells into iPS cells

Pay-for-performance program may cause inequalities among healthcare providers

Two laboratory methods for Drosophila Neurobiology featured in Cold Spring Harbor Protocols journal

Book on governance, social justice and epidemic diseases

Scientists explain mechanism behind acute myeloid leukemia

Diagnostic Hybrids receives Chinese SFDA approval for D3 Ultra DFA Respiratory Virus Screening and ID Kit

Advanced Life Sciences prices securities offering

AstraZeneca announces new support program for patients on ARIMIDEX

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Ecolab launches Virasept to treat Clostridium difficile spores

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

Investment report on BioCryst Pharmaceuticals

Medivir's rights issue changes number of shares and votes

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in